A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
← catalyst calendarNCT07722767 · readout in 406 d
Sponsored by Cullinan Therapeutics Inc. (industry) · CGEM — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
90estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-10-15 | estimated | When the study began enrolling |
| Primary completion | 2027-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- AML (Acute Myeloid Leukemia)
Interventions
- Drug: CLN-049
- Drug: Azacitidine
- Drug: Venetoclax
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclax
measured 48 weeks
Determine recommended dose/schedule of CLN-049 in combination with azacitidine and venetoclax
measured 48 weeks
Permalink · CGEM's whole pipeline · Catalyst calendar · Every registered study · What changed